XFOR Q3 EPS Forecast Lifted by Brookline Capital Markets

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) – Research analysts at Brookline Capital Markets upped their Q3 2026 EPS estimates for shares of X4 Pharmaceuticals in a report released on Tuesday, September 8th. Brookline Capital Markets analyst L. Cann now expects that the company will post earnings per share of ($0.20) for the quarter, up from their prior forecast of ($0.22). The consensus estimate for X4 Pharmaceuticals’ current full-year earnings is ($0.71) per share. Brookline Capital Markets also issued estimates for X4 Pharmaceuticals’ Q4 2026 earnings at ($0.25) EPS, FY2026 earnings at ($0.71) EPS, FY2027 earnings at ($0.90) EPS, FY2028 earnings at ($1.29) EPS, FY2029 earnings at ($0.15) EPS and FY2030 earnings at $2.86 EPS.

A number of other research firms also recently issued reports on XFOR. Leerink Partners assumed coverage on X4 Pharmaceuticals in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $12.00 price target on the stock. Weiss Ratings raised shares of X4 Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 25th. Finally, Wells Fargo & Company initiated coverage on shares of X4 Pharmaceuticals in a research report on Friday, July 10th. They issued an “overweight” rating and a $11.00 price target for the company. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $11.25.

X4 Pharmaceuticals Stock Down 5.6%

XFOR opened at $3.40 on Friday. X4 Pharmaceuticals has a one year low of $2.80 and a one year high of $4.83. The company has a debt-to-equity ratio of 0.49, a quick ratio of 11.02 and a current ratio of 11.30. The stock has a market capitalization of $337.11 million, a P/E ratio of -2.83 and a beta of 0.39. The business’s 50-day simple moving average is $4.03 and its 200-day simple moving average is $4.03.

X4 Pharmaceuticals (NASDAQ:XFOR) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.05. X4 Pharmaceuticals had a negative net margin of 568.80% and a negative return on equity of 63.05%. The firm had revenue of $8.81 million during the quarter, compared to analysts’ expectations of $2.42 million.

Insider Activity at X4 Pharmaceuticals

In other X4 Pharmaceuticals news, Chairman Adam Craig sold 47,436 shares of the company’s stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $4.44, for a total transaction of $210,615.84. Following the completion of the sale, the chairman directly owned 328,651 shares of the company’s stock, valued at $1,459,210.44. This represents a 12.61% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO David Kirske sold 8,543 shares of the stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $4.26, for a total value of $36,393.18. Following the sale, the chief financial officer directly owned 167,750 shares of the company’s stock, valued at $714,615. The trade was a 4.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 80,555 shares of company stock worth $356,126 in the last quarter. Company insiders own 1.13% of the company’s stock.

Institutional Investors Weigh In On X4 Pharmaceuticals

Large investors have recently modified their holdings of the stock. Perceptive Advisors LLC increased its stake in shares of X4 Pharmaceuticals by 6.7% during the first quarter. Perceptive Advisors LLC now owns 6,737,648 shares of the company’s stock worth $27,826,000 after acquiring an additional 423,196 shares during the period. Empery Asset Management LP acquired a new stake in X4 Pharmaceuticals in the fourth quarter valued at about $35,804,000. Bank of New York Mellon Corp acquired a new stake in X4 Pharmaceuticals in the second quarter valued at about $917,000. Squarepoint Ops LLC purchased a new stake in X4 Pharmaceuticals in the 2nd quarter valued at approximately $313,000. Finally, AXQ Capital LP acquired a new position in X4 Pharmaceuticals during the 2nd quarter worth approximately $107,000. Hedge funds and other institutional investors own 72.03% of the company’s stock.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.